ProCE Banner Series

Practical Guidance for the Multidisciplinary Team on Therapeutics Targeting Protein Degradation Pathways in NHL

Register now for this interactive workshop series to learn more about the rationale for targeting protein degradation pathways in non-Hodgkin lymphoma (NHL), and the emerging role of cereblon E3 ligase modulators (CELMoDs) in the personalized care of patients with NHL. After the meeting, download the associated slideset for use in your clinic.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the management of NHL.

All Events

Practical Guidance for the Multidisciplinary Team on Therapeutics Targeting Protein Degradation Pathways in NHL

Upcoming Events

December

04

2024

8:00 AM - 9:00 AM Pacific Time (PT)

Virtual

CCO Simulcast | Host Group ID, Post Falls, Idaho

January

22

2025

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

Private Event | Host Group MD, Rockville, Maryland

Past Events

November

07

2024

8:30 AM - 9:30 AM Central Time (CT)

Virtual

CCO Simulcast | Host Group TX, Pittsburg, Texas

Faculty

ProCE Banner Faculty
John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, New York

ProCE Banner Faculty
Julio C Chavez, MD, MS

Associate Member
ICE-T Clinical Research Medical Director Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida

ProCE Banner Faculty
Nathan Denlinger, DO, MS

Assistant Professor, BMT & Cell Therapy
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

ProCE Banner Faculty
Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

ProCE Banner Faculty
Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

ProCE Banner Faculty
Alan Skarbnik, MD

Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve learners’ understanding of the latest data on investigational protein degradation pathway inhibitors for the treatment of NHL in preparation for clinical use of these agents. 

Target Audience
This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the management of NHL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the unique mechanism of action of CELMoDs in NHL, including anti-malignant effects as well as modulation of non-malignant components of the tumor microenvironment
  • Evaluate the efficacy data as well as safety and tolerability profiles of investigational agents that target protein degradation pathways in NHL treatment, specifically considering the potential clinical application of CELMoDs
  • Identify eligible patients with NHL who are candidates for enrollment on ongoing clinical trials evaluating novel protein degraders

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacotherapy credit.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: Specific to each event.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which included participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

ILNA Recertification Points
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

  • Care Continuum (OCN®, CBCN®, CPHON®, AOCNP®)
  • Care of the Pediatric Hematology and Oncology Patient (CPHON®)
  • Foundations of Transplant (BMTCN®)
  • Nursing Practice (CBCN®)
  • Oncologic Emergencies (OCN®, CPHON®, AOCNP®)
  • Oncology Nursing Practice (OCN®)
  • Pediatric Hematology and Oncology Nursing Practice (CPHON®)
  • Professional Practice / Performance (BMTCN®, AOCNP®)
  • Psychosocial Dimensions of Care (AOCNP®, CPHON®, OCN®, CBCN®)
  • Quality of Life (BMTCN®)
  • Roles of the APRN (AOCNP®)
  • Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)
  • Transplant Process and Infusion (BMTCN®)
  • Treatment (OCN®, CBCN®, AOCNP®, CPHON®)

Total Points: 1.0*

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area.  The total amount of ILNA points claimed may not exceed the total amount of nursing continuing professional development (NCPD) awarded from this course.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Bristol Myers Squibb.